Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.>
You can use a suffix operator (*) as the placeholder for end of a term. The query must start with at least one alphanumeric character before the suffix operator. E.g., Rifam* will get you “Rifampicin” and “Rifampin”. For more advanced searching tips click here.
Brand Name(s) include: Emtriva, Truvada
Disease: HIV
Drug Class: Nucleoside reverse transcriptase inhibitor
Date of Review: 2020
Number of Models Reviewed: 2
Number of Models added to the Repository: 2
Publication |
De Sousa Mendes, M., Hirt, D., Urien, S., Valade, E., Bouazza, N., Foissac, F., Blanche, S., Treluyer, J. M., & Benaboud, S. (2015). Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. British journal of clinical pharmacology, 80(5), 1031–1041. |
Simcyp Version |
V13 |
Published Model Application |
Prediction of exposure in pregnancy |
Absorption Model |
First Order |
Volume of Distribution Details |
Full PBPK |
Route of Elimination |
|
Perpetrator DDI |
|
Advantages and Limitations |
|
Model Compound Files |
|
Publication |
De Sousa Mendes M, Chetty M. Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Drugs R D. 2019 Dec;19(4):339-350. |
Simcyp Version |
V17 |
Published Model Application |
Prediction of exposure in renal impairment |
Absorption Model |
First Order |
Volume of Distribution Details |
Full PBPK |
Route of Elimination |
|
Perpetrator DDI |
|
Advantages and Limitations |
|
Model Compound Files |
|
Three compound files for adults and 3 files for paediatrics are available for the parent compounds, Valproic Acid, reflecting the inputs required for EC tablets, tablets, and capsules, respectively. A compound file for the metabolite, 4-ene-Valproid Acid is available too. Details on the model assumptions and verification in V21R1 are available in the corresponding reference (DOI: 10.1002/psp4.13045) and supplement material on the journal (CPT: Pharmacometrics & Systems Pharmacology) website.
11 |
> |
>| |